Genetic Variation in KCNH2 and a Unique hERG Isoform in Patients With Schizophrenia: Efficacy-Safety Link.

摘要

Based on the results of an NIMH double-blind trial and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, Apud et al. (1) have provided support for the hypothesis of Huffaker et al. (2) that a genetic variation in the hERG1 protein, the KCNH2 3.1 isoform, may be related to treatment response. Could this hypothesis be extended to personalized medicine to minimize the risk of dysrhythmias related to QTc prolongation by giving anti-psychotics only to those who will benefit from them? Or better, could we de-risk compounds by developing more targeted drugs that only bind to brain KCNH2 3.1?